Biozeen, a total solutions provider for the biotech industry, is scouting for acquisition of small and medium companies in the design build solutions (DBS) space. In 2007, it proved its highest competence in the DBS segment. This has led Biozeen to close its annual revenues at Rs 15 crore ending March 2008 with over 50 per cent coming in from export markets.
There was considerable value addition in terms of demanding projects in DBS. From 42 projects in 2007 to 118 assignments in the last 11 months, Biozeen is positive that it will have 200 customers by the end of 2008.
In the DBS business, Biozeen manufactures customized and standard bioprocess equipment compliant to ASME-BPE,GAMP-4 and 21 CFR PART 11 at its state-of-the-art production facility on the 10-acre campus off Hennur in Bangalore.
"Charting the acquisition route will help the company strengthen its international operations and gain a foothold into readymade global client base. Acquisitions will help us broaden our base without having to compete in a stiff export market," Dr. Anil Paul Kariath, president, consulting and training, Biozeen told Pharmabiz.
Going by the company's core competence in conceptual design, project management, process evaluation and failure analysis, it was a deliberate decision to be in the DBSs space, he added.
In the last three years, the company has proved its capability as a single source suppler in bio-process engineering. It now plans to grow fast through the acquisition route. The ability to acquire companies stems from an innate confidence that comes from our domain expertise and makes us a veritable techno investor, explained Dr Kariath.
The company specializes in the design and delivery of cGMP process technology. It offers turn key solutions across project lifecycles in process engineering and equipment design, support in procurement and validation of equipment-facility, besides assisting in commissioning and research process optimization.
Right now Biozeen is consolidating its contract manufacture business. Over 80 per cent new contracts are from exports. These include bio-process equipment supplies, Cleaning-In-Place (CIP) and Sterilization-In-Place (SIP) systems designed for automatic cleaning and disinfecting. The company is known for its reliable and economical solutions which save money through higher plant utilization, optimal use of resources and man hours for its customers. The CIP and SIP are critical components pharma, biotech, nutraceutical, food, dairy, beverage, cosmetic industries where hygienic and aseptic environment is vital.
The company has also started operations in the US last year where it has hired two consultants for DBS.
The expertise at Biozeen is led by Cherian Philip and Dr Karaith who pioneered innovative world class fermentation technology in India while at Sartorius India with over three decades of experience in biotech engineering.